Issue Date: June 19, 2017
Johnson Matthey teams with Intrexon
Johnson Matthey and and Intrexon, a Budapest-based biopharmaceutical firm, will jointly develop microbial strains for the production of peptide-based active pharmaceutical ingredients (APIs) via fermentation. Intrexon will contribute its proprietary microbial hosts and fermentation processes to the initial fermentation, isolation, and purification of APIs. Johnson Matthey will be responsible for scale-up, formulation, and commercialization of microbial strains.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society